NAGE Niagen Bioscience, Inc.
Company Analysis
Latest News
🔴 Niagen Bioscience is trading 10.12% down today after Q3 sales miss and weaker ingredient outlook
Niagen Bioscience is trading at $2.23, down 10.12%, after November 4 earnings missed expectations and management tempered its outlook. - Q3 sales were $27.2...
🔴 Niagen Bioscience is trading 10% down today after Q3 revenue missed analyst expectations
Niagen Bioscience is trading at $2.27, down 9.96%, after third-quarter revenue fell 20% year over year. - November 4 results showed revenue of $27.2 million,...
🔴 Niagen Bioscience is trading 8.4% down in pre-market after revenue fell 20% and missed estimates
Niagen Bioscience is trading 8.41% down at $2.31 in pre-market after its November 4 report showed third-quarter revenue of $27.2 million, down 20% year over...
Niagen Bioscience Posts Sharp Revenue Drop and a Loss — Can a $69 Million Cash Pile Buy Enough Time to Turn Things Around?
Shares of Niagen Bioscience (NAGE) slid 9.5% to $2.28 after the dietary-supplement and longevity-science company disclosed a third quarter that fell short on...
🔴 Niagen Bioscience is trading 9.52% down in after-hours trading after third-quarter revenue and earnings missed expectations
Niagen Bioscience is trading at $2.28, down 9.52%, after its November 4 release showed third-quarter revenue and earnings missed expectations. - Revenue was...
Niagen Bioscience's third quarter revenue of $27.2M missed estimates amid competitive ingredient market headwinds
Niagen Bioscience reported a 20% year-over-year decline in third quarter 2026 revenue to $27.2 million, significantly missing the $33.7 million analyst...
🟢 Niagen Bioscience is trading 6.8% up on November 4 amid U.S. futures rebound after midterm results
Niagen Bioscience is trading at $2.53, up 6.84%, amid a broader market rebound after midterm results. - No company-specific catalyst was confirmed for the...
🟢 Niagen Bioscience is trading 6% up in pre-market with no confirmed catalyst
Niagen Bioscience is trading at $2.50, up +5.93% in pre-market; no stock-specific catalyst has been confirmed. - U.S. indices are reported higher by more than...
Niagen Bioscience, Inc. Q3 2026 Earnings Preview: What Analysts Expect on November 04, 2026
Niagen Bioscience is expected to report Q3 2026 revenue of $33.71 million and EPS of $0.01, with its current $2.33 stock price trading significantly below the...
🔴 Niagen Bioscience is trading 5.8% down
Niagen Bioscience is trading 5.8% down at $2.35 on October 30, 2026; the specific catalyst remains unclear. - No new company announcement was found clearly...
🟢 Niagen Bioscience is trading 9.33% up in pre-market
Niagen Bioscience is trading at $2.93, up 9.33% in pre-market, with broader market gains potentially supporting the move; no company-specific catalyst has...
🔴 Niagen Bioscience is trading 5% down
Niagen Bioscience is trading 5.31% down now at $2.77, with no company-specific announcement or catalyst surfaced for October 1, 2026. - A market listing...
🔴 Niagen Bioscience is trading 5.02% down today as biotech ETF XBI falls 4.24%
Niagen Bioscience is trading now at $3.12, down 5.02%, with sector pressure the primary explanation after no clear company-specific catalyst emerged on August...
🔴 Niagen Bioscience is trading 6.23% down in pre-market with no clear catalyst identified
Niagen Bioscience is trading 6.23% down at $3.01 after falling from the August 27 close of $3.21, with no clear catalyst identified. - No credible August 28,...
Niagen Bioscience expands Tru Niagen retail reach, meeting healthy aging demand
Niagen Bioscience launched its flagship Tru Niagen® NAD+ supplement at GNC and Sam's Club stores and websites. This expansion adds nearly 300 retail locations...
🟢 Niagen Bioscience rises 5.4% — Biotech Sector Surges on Positive mRNA Cancer Vaccine Trial Results
With Biotech (XBI) up 3.7%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, proxied by the XBI ETF, is trading...
Niagen Bioscience's Revenue Miss Raises a Hard Question: Can Online Supplement Sales Alone Carry a $270 Million Company?
Shares plunged 8.4% to $3.18 after hours as Niagen Bioscience's second-quarter results exposed a widening crack between the company's fastest-growing channel...
🟢 Niagen Bioscience is trading 6.5% up in pre-market after rebounding from August 6 close
Niagen Bioscience is trading at $3.24, up +6.47% in pre-market after closing at $3.04 on August 6, 2026. - No major company-specific announcement was...
🔴 Niagen Bioscience is trading 15.9% down today after Q2 revenue miss and rising marketing expenses
Niagen Bioscience is trading 15.9% down at $3.12 after its Q2 revenue missed analyst estimates and marketing costs surged. • Net sales reached $29.8 million,...
🔴 Niagen Bioscience is trading 8.4% down today after Q2 revenue missed analyst estimates
Niagen Bioscience is trading at $3.18 (-8.36%) after hours following second-quarter results that disappointed on the top line. • The company reported $29.8...